# A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

> **NCT05415215** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 346 (actual)

## Conditions studied

- Early Breast Cancer
- Locally Advanced Breast Cancer
- Inflammatory Breast Cancer

## Interventions

- **DRUG:** Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
- **DRUG:** Pertuzumab IV
- **DRUG:** Trastuzumab IV
- **DRUG:** Trastuzumab Emtansine
- **DRUG:** Investigator's Choice of Chemotherapy
- **PROCEDURE:** Surgery
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05415215
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-05
- **Primary completion:** 2024-11-20
- **Final completion:** 2025-11-07
- **Target enrollment:** 346 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05415215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05415215, "A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05415215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*